Chinese Pre-Profit Cancer Drug Developer Tot Biopharm Files For HK IPO

Tot Biopharm, a private equity-backed Chinese biopharmaceutical company, has filed for an initial public offering (IPO) in Hong Kong on Monday under the rules that allow pre-profit companies to float shares on the stock exchange.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in